Bayko Liisa Ann 4

What Happened

• Liisa Bayko, Chief Financial Officer of Kalaris Therapeutics (KLRS), received a grant of derivative securities covering 220,000 shares on July 20, 2026. The filing reports an acquisition price of $0.00 for the award (transaction code A), and the reported total value of the grant in the Form 4 is $0.00. This is a compensation equity grant (an award of options or similar derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-20 (filed same day; filing appears timely)
• Transaction type/code: Award/Grant (A) of a derivative security
• Shares underlying grant: 220,000
• Reported acquisition price/value: $0.00 (derivative award)
• Vesting: 25% vests on July 20, 2027; remaining shares vest in equal monthly installments over the following three years, subject to continuous service (see footnote)
• Shares owned after transaction: Not specified in the information provided here — check the full Form 4 for beneficial ownership totals
• No sale or exercise reported — this is a grant, not an immediate cash transaction

Context

• This grant is a typical equity compensation award for an executive and does not indicate any immediate sale or purchase of shares. Vesting is time-based and subject to continued employment; the award will only convert to vested shares over the four-year schedule. For details such as the exercise price, acceleration provisions, or full ownership totals, review the complete Form 4 filing.